Published • loading... • Updated
Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
Summary by The Manila Times
6 Articles
6 Articles
St Catharines Standard+5 Reposted by 5 other sources
Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel, therapeutics for autism spectrum disorder…
·Welland, Canada
Read Full ArticleCoverage Details
Total News Sources6
Leaning Left5Leaning Right1Center0Last UpdatedBias Distribution83% Left
Bias Distribution
- 83% of the sources lean Left
83% Left
L 83%
R 17%
Factuality
To view factuality data please Upgrade to Premium
